US 505(b)(2) Regulatory Pathway and Strategies

More documents

Recommendations

Info

Decision to Pursue the 505(b)(2) Regulatory PathwayConsiderations:• Willingness to take educated risks• In-house Expertise• Company Culture• Historical Precedence24
Thank You• Regulatory Sciences Co-Moderators– Michael Bornstein, PhD– Annette Bak, PhD, MBA• Rajneesh Taneja, PhD, RPh
Page 1 and 2: US 505(b)(2) RegulatoryPathway and
Page 3 and 4: Differentiated Products Now Essenti
Page 5 and 6: 505(b)(2) RegulationPotential 505(b
Page 7 and 8: 505(b)(2) NDAReference Listed Drug
Page 9 and 10: Industry ExamplesHighlighting the B
Page 11 and 12: Corporate StrategyMr. Sims: Actuall
Page 13 and 14: Case Study: Ulesfia TM - Excipient
Page 15 and 16: Pro-Drugs• Fundamental:- Where do
Page 17 and 18: Valacyclovir Regulatory Path• 505
Page 19 and 20: Benefits of 505(b)(2)• Get out of
Page 21 and 22: 505(b)(2) Risks• Uncertain market
Page 23: 505(b)(2) Risks• Like Generics (5

US 505(b)(2) Regulatory Pathway and Strategies

Create successful ePaper yourself

Delete template?

Save as template?